Anti-MOG autoantibodies in Italian multiple sclerosis patients: Specificity, sensitivity and clinical association

Renato Mantegazza, Piercarlo Cristaldini, Pia Bernasconi, Fulvio Baggi, Rosetta Pedotti, Ilaria Piccini, Nerina Mascoli, Loredana La Mantia, Carlo Antozzi, Ornella Simoncini, Ferdinando Cornelio, Clara Milanese

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

There is considerable evidence that multiple sclerosis (MS) is an immune-mediated disease characterized by infiltration of inflammatory cells into the CNS and demyelination. Several myelin proteins may be encephalitogenic, including myelin basic protein, proteolipid protein and myelin oligodendrocyte glycoprotein (MOG), the latter being expressed on the external layer of myelin sheaths and hence accessible to antibody attack. We investigated MOG autoreactivity in serum and cerebrospinal fluid (CSF) by ELISA, employing the recombinant extracellular domain of MOG as antigen. We tested serum samples from 262 MS patients (175 relapsing-remitting, 43 primary progressive and 44 secondary progressive), 131 patients with other neurological diseases (OND) and 307 healthy controls. No patients or controls were receiving immunomodulating treatments. We found anti-MOG antibodies in the serum of 13.7% MS patients, mainly in those with secondary progressive MS (25%), in 13.7% of OND patients and in 6.2% of controls. We found a direct correlation (R2 = 0.6, P = 0.002) between disease severity and anti-MOG titer only in patients with primary and secondary progressive MS. Anti-MOG antibodies were present in the CSF of 11.4% MS patients and 18.9% OND patients. Intrathecal synthesis of anti-MOG antibodies was demonstrated in four (4.5%) of MS patients and no OND patients. Anti-MOG antibodies are not specific for MS; however, they may characterize a subset of MS patients and this may be revealed by serial assays in relation to changing disease phase.

Original languageEnglish
Pages (from-to)559-565
Number of pages7
JournalInternational Immunology
Volume16
Issue number4
DOIs
Publication statusPublished - Apr 2004

Fingerprint

Myelin-Oligodendrocyte Glycoprotein
Autoantibodies
Multiple Sclerosis
Sensitivity and Specificity
Chronic Progressive Multiple Sclerosis
Antibodies
Cerebrospinal Fluid
Serum
Proteolipids
Myelin Proteins
Myelin Basic Protein
Immune System Diseases
Demyelinating Diseases
Myelin Sheath

Keywords

  • Antibody
  • Antibody index
  • Autoimmunity
  • Multiple sclerosis
  • Myelin oligodendrocyte glycoprotein

ASJC Scopus subject areas

  • Immunology

Cite this

Anti-MOG autoantibodies in Italian multiple sclerosis patients : Specificity, sensitivity and clinical association. / Mantegazza, Renato; Cristaldini, Piercarlo; Bernasconi, Pia; Baggi, Fulvio; Pedotti, Rosetta; Piccini, Ilaria; Mascoli, Nerina; La Mantia, Loredana; Antozzi, Carlo; Simoncini, Ornella; Cornelio, Ferdinando; Milanese, Clara.

In: International Immunology, Vol. 16, No. 4, 04.2004, p. 559-565.

Research output: Contribution to journalArticle

Mantegazza, Renato ; Cristaldini, Piercarlo ; Bernasconi, Pia ; Baggi, Fulvio ; Pedotti, Rosetta ; Piccini, Ilaria ; Mascoli, Nerina ; La Mantia, Loredana ; Antozzi, Carlo ; Simoncini, Ornella ; Cornelio, Ferdinando ; Milanese, Clara. / Anti-MOG autoantibodies in Italian multiple sclerosis patients : Specificity, sensitivity and clinical association. In: International Immunology. 2004 ; Vol. 16, No. 4. pp. 559-565.
@article{6666ba1befb1461cbaa193f0309c8f7b,
title = "Anti-MOG autoantibodies in Italian multiple sclerosis patients: Specificity, sensitivity and clinical association",
abstract = "There is considerable evidence that multiple sclerosis (MS) is an immune-mediated disease characterized by infiltration of inflammatory cells into the CNS and demyelination. Several myelin proteins may be encephalitogenic, including myelin basic protein, proteolipid protein and myelin oligodendrocyte glycoprotein (MOG), the latter being expressed on the external layer of myelin sheaths and hence accessible to antibody attack. We investigated MOG autoreactivity in serum and cerebrospinal fluid (CSF) by ELISA, employing the recombinant extracellular domain of MOG as antigen. We tested serum samples from 262 MS patients (175 relapsing-remitting, 43 primary progressive and 44 secondary progressive), 131 patients with other neurological diseases (OND) and 307 healthy controls. No patients or controls were receiving immunomodulating treatments. We found anti-MOG antibodies in the serum of 13.7{\%} MS patients, mainly in those with secondary progressive MS (25{\%}), in 13.7{\%} of OND patients and in 6.2{\%} of controls. We found a direct correlation (R2 = 0.6, P = 0.002) between disease severity and anti-MOG titer only in patients with primary and secondary progressive MS. Anti-MOG antibodies were present in the CSF of 11.4{\%} MS patients and 18.9{\%} OND patients. Intrathecal synthesis of anti-MOG antibodies was demonstrated in four (4.5{\%}) of MS patients and no OND patients. Anti-MOG antibodies are not specific for MS; however, they may characterize a subset of MS patients and this may be revealed by serial assays in relation to changing disease phase.",
keywords = "Antibody, Antibody index, Autoimmunity, Multiple sclerosis, Myelin oligodendrocyte glycoprotein",
author = "Renato Mantegazza and Piercarlo Cristaldini and Pia Bernasconi and Fulvio Baggi and Rosetta Pedotti and Ilaria Piccini and Nerina Mascoli and {La Mantia}, Loredana and Carlo Antozzi and Ornella Simoncini and Ferdinando Cornelio and Clara Milanese",
year = "2004",
month = "4",
doi = "10.1093/intimm/dxh056",
language = "English",
volume = "16",
pages = "559--565",
journal = "International Immunology",
issn = "0953-8178",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Anti-MOG autoantibodies in Italian multiple sclerosis patients

T2 - Specificity, sensitivity and clinical association

AU - Mantegazza, Renato

AU - Cristaldini, Piercarlo

AU - Bernasconi, Pia

AU - Baggi, Fulvio

AU - Pedotti, Rosetta

AU - Piccini, Ilaria

AU - Mascoli, Nerina

AU - La Mantia, Loredana

AU - Antozzi, Carlo

AU - Simoncini, Ornella

AU - Cornelio, Ferdinando

AU - Milanese, Clara

PY - 2004/4

Y1 - 2004/4

N2 - There is considerable evidence that multiple sclerosis (MS) is an immune-mediated disease characterized by infiltration of inflammatory cells into the CNS and demyelination. Several myelin proteins may be encephalitogenic, including myelin basic protein, proteolipid protein and myelin oligodendrocyte glycoprotein (MOG), the latter being expressed on the external layer of myelin sheaths and hence accessible to antibody attack. We investigated MOG autoreactivity in serum and cerebrospinal fluid (CSF) by ELISA, employing the recombinant extracellular domain of MOG as antigen. We tested serum samples from 262 MS patients (175 relapsing-remitting, 43 primary progressive and 44 secondary progressive), 131 patients with other neurological diseases (OND) and 307 healthy controls. No patients or controls were receiving immunomodulating treatments. We found anti-MOG antibodies in the serum of 13.7% MS patients, mainly in those with secondary progressive MS (25%), in 13.7% of OND patients and in 6.2% of controls. We found a direct correlation (R2 = 0.6, P = 0.002) between disease severity and anti-MOG titer only in patients with primary and secondary progressive MS. Anti-MOG antibodies were present in the CSF of 11.4% MS patients and 18.9% OND patients. Intrathecal synthesis of anti-MOG antibodies was demonstrated in four (4.5%) of MS patients and no OND patients. Anti-MOG antibodies are not specific for MS; however, they may characterize a subset of MS patients and this may be revealed by serial assays in relation to changing disease phase.

AB - There is considerable evidence that multiple sclerosis (MS) is an immune-mediated disease characterized by infiltration of inflammatory cells into the CNS and demyelination. Several myelin proteins may be encephalitogenic, including myelin basic protein, proteolipid protein and myelin oligodendrocyte glycoprotein (MOG), the latter being expressed on the external layer of myelin sheaths and hence accessible to antibody attack. We investigated MOG autoreactivity in serum and cerebrospinal fluid (CSF) by ELISA, employing the recombinant extracellular domain of MOG as antigen. We tested serum samples from 262 MS patients (175 relapsing-remitting, 43 primary progressive and 44 secondary progressive), 131 patients with other neurological diseases (OND) and 307 healthy controls. No patients or controls were receiving immunomodulating treatments. We found anti-MOG antibodies in the serum of 13.7% MS patients, mainly in those with secondary progressive MS (25%), in 13.7% of OND patients and in 6.2% of controls. We found a direct correlation (R2 = 0.6, P = 0.002) between disease severity and anti-MOG titer only in patients with primary and secondary progressive MS. Anti-MOG antibodies were present in the CSF of 11.4% MS patients and 18.9% OND patients. Intrathecal synthesis of anti-MOG antibodies was demonstrated in four (4.5%) of MS patients and no OND patients. Anti-MOG antibodies are not specific for MS; however, they may characterize a subset of MS patients and this may be revealed by serial assays in relation to changing disease phase.

KW - Antibody

KW - Antibody index

KW - Autoimmunity

KW - Multiple sclerosis

KW - Myelin oligodendrocyte glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=11144358095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144358095&partnerID=8YFLogxK

U2 - 10.1093/intimm/dxh056

DO - 10.1093/intimm/dxh056

M3 - Article

C2 - 15039386

AN - SCOPUS:11144358095

VL - 16

SP - 559

EP - 565

JO - International Immunology

JF - International Immunology

SN - 0953-8178

IS - 4

ER -